Luis Jara-Palomares

Dr. Luis Jara-Palomares

Virgen del Rocio Hospital, Sevilla, Spain
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in The Lancet Oncology
Verified
Journal Article
Closed access
DFDominique Farge
Dominique Farge
CFCorinne Frere
Corinne Frere
JCJean M Connors
Jean M Connors
Cihan AyCihan Ay
Cihan Ay
AKAlok A Khorana
Alok A Khorana
NYNorizaku Yamada
Norizaku Yamada

7 December 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
FKFrederikus A. Klok
Frederikus A. Klok
WAWalter Ageno
Walter Ageno
Cihan AyCihan Ay
Cihan Ay
MBMagnus Bäck
Magnus Bäck
SBStefano Barco
Stefano Barco
PPPiotr Pruszczyk
Piotr Pruszczyk
This position paper provides a comprehensive guide for optimal follow-up of patients with acute pulmonary embolism (PE), covering multiple relevant aspects of patient counselling. It serves as a practical guide to treating patients with acute PE complementary to the formal 2019 European Society of Cardiology guidelines developed with the European Respiratory Society. We propose a holistic approach considering the whole spectrum of serious adverse events that patients with acute PE may encounter on the short and long run. We underline the relevance of assessment of modifiable risk factors for bleeding, of acquired thrombophilia and limited cancer screening (unprovoked PE) as well as a dedicated surveillance for the potential development of chronic thromboembolic pulmonary hypertension as part of routine practice; routine testing for genetic thrombophilia should be avoided. We advocate the use of outcome measures for functional outcome and quality of life to quantify the impact of the PE diagnosis and identify patients with the post-PE syndrome early. Counselling patients on maintaining a healthy lifestyle mitigates the risk of the post-PE syndrome and improves cardiovascular prognosis. Therefore, we consider it important to discuss when and how to resume sporting activities soon after diagnosing PE. Additional patient-relevant topics that require Focused counselling are travel and birth control.

19 September 2017 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
NENick van Es
Nick van Es
GGGrégoire Le Gal
Grégoire Le Gal
HOHans-Martin Otten
Hans-Martin Otten
PRPhilippe Robin
Philippe Robin
APAndrea Piccioli
Andrea Piccioli
MCMarc Carrier
Marc Carrier
Screening for cancer in patients with unprovoked venous thromboembolism (VTE) often is considered, but clinicians need precise data on cancer prevalence, risk factors, and the effect of different types of screening strategies. To estimate the prevalence of occult cancer in patients with unprovoked VTE, including in subgroups of different ages or those that have had different types of screening. MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to 19 January 2016. Prospective studies evaluating cancer screening strategies in adults with unprovoked VTE that began enrolling patients after 1 January 2000 and had at least 12 months of follow-up. 2 investigators independently reviewed abstracts and full-text articles and independently assessed risk of bias. 10 eligible studies were identified. Individual data were obtained for all 2316 patients. Mean age was 60 years; 58% of patients received extensive screening. The 12-month period prevalence of cancer after VTE diagnosis was 5.2% (95% CI, 4.1% to 6.5%). The point prevalence of cancer was higher in patients who had extensive screening than in those who had more limited screening initially (odds ratio [OR], 2.0 [CI, 1.2 to 3.4]) but not at 12 months (OR, 1.4 [CI, 0.89 to 2.1]). Cancer prevalence increased linearly with age and was 7-fold higher in patients aged 50 years or older than in younger patients (OR, 7.1 [CI, 3.1 to 16]). Variation in patient characteristics and extensive screening strategies; unavailability of long-term mortality data. Occult cancer is detected in 1 in 20 patients within a year of receiving a diagnosis of unprovoked VTE. Older age is associated with a higher cancer prevalence. Although an extensive screening strategy initially may detect more cancer cases than limited screening, whether this translates into improved patient outcomes remains unclear. None. (PROSPERO: CRD42016033371)

1 September 2017 in Thrombosis Research
Verified
Journal Article
Open access
Luis Jara-PalomaresLuis Jara-Palomares
Luis Jara-Palomares
ASAurora Solier-Lopez
Aurora Solier-Lopez
THTeresa Elias Hernandez
Teresa Elias Hernandez
MAMaribel Asensio-Cruz
Maribel Asensio-Cruz
IBIsabel Blasco-Esquivias
Isabel Blasco-Esquivias
RORemedios Otero
Remedios Otero
The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1-6 and 7-12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p=0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p=0.02). The incidence of VTE recurrence at months 1-6 and 7-12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Treatment with tinzaparin beyond 6months is safe in patients with CAT.

6 February 2015 in Thorax
Verified
Journal Article
Closed access
PDF file
SVSimone Vanni
Simone Vanni
DJDavid Jiménez
David Jiménez
PNPeiman Nazerian
Peiman Nazerian
FMFulvio Morello
Fulvio Morello
MPMichele Parisi
Michele Parisi
SGStefano Grifoni
Stefano Grifoni
Background Strategies for identifying normotensive patients with acute symptomatic PE at high risk of PE-related complications remain to be defined. Methods This prospective cohort study aimed to determine the role of plasma lactate levels in the risk assessment of normotensive patients with acute PE. Outcomes assessed over the 7 days after the diagnosis of PE included PE-related mortality and haemodynamic collapse, defined as need for cardiopulmonary resuscitation, systolic blood pressure <90 mm Hg for at least 15 min, need for catecholamine administration, or need for mechanical ventilation. Results Between December 2012 and January 2014, the study enrolled 496 normotensive outpatients with acute symptomatic PE. PE-related complications occurred in 20 (4.0%; 95% CI 2.5% to 6.2%) of the 496 patients. These patients had higher baseline lactate levels (median 2.66 mmol/L; IQR 1.56–5.96 mmol/L) than patients without complications (1.20 mmol/L; IQR 1.20–2.00 mmol/L) (p<0.001). Overall, 135 patients (27.2%) had plasma lactate ≥2 mmol/L. Fourteen (10.4%) of them had PE-related complications versus 6 of 361 patients with low lactate (negative predictive value 98.3%; p<0.001). Patients with elevated plasma lactate had an increased rate of PE-related complications (adjusted OR 5.3; 95% CI 1.9 to 14.4; p=0.001) compared with those with low lactate. The combination of elevated plasma lactate with markers of right ventricular dysfunction (by echocardiogram) and myocardial injury (by cardiac troponin) was a particularly useful prognostic indicator (positive predictive value 17.9%; 95% CI 6.1% to 36.9%). Conclusions Plasma lactate represents a powerful predictor of short-term PE-related complications and may provide guidance for decision-making in PE care.

1 March 2017 in The American Journal of Medicine
Verified
Journal Article
Closed access
Isabelle MahéIsabelle Mahé
Isabelle Mahé
JCJean Chidiac
Jean Chidiac
LBLaurent Bertoletti
Laurent Bertoletti
CFCarme Font
Carme Font
JTJavier Trujillo-Santos
Javier Trujillo-Santos
ARAbilio Reis
Abilio Reis